Compare JFU & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFU | NMTC |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.7M | 39.5M |
| IPO Year | 2018 | 2010 |
| Metric | JFU | NMTC |
|---|---|---|
| Price | $3.08 | $3.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.90 |
| AVG Volume (30 Days) | 7.2K | ★ 33.2K |
| Earning Date | 12-09-2022 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,097,692.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $31.90 |
| P/E Ratio | $1.43 | ★ N/A |
| Revenue Growth | N/A | ★ 163.47 |
| 52 Week Low | $1.25 | $0.55 |
| 52 Week High | $9.48 | $5.40 |
| Indicator | JFU | NMTC |
|---|---|---|
| Relative Strength Index (RSI) | 41.97 | 43.67 |
| Support Level | $2.65 | $0.69 |
| Resistance Level | $4.79 | $4.87 |
| Average True Range (ATR) | 0.47 | 0.37 |
| MACD | -0.07 | -0.20 |
| Stochastic Oscillator | 7.07 | 0.83 |
9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.